AmpliPhi Biosciences Announces Topline Results from Its Phase 1 Phage Therapy Trial Conducted in the United States
/in Portfolio CompaniesTuesday, September 13, 2016. Link here. NYSEMKT:APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced topline data from a Phase 1 trial to evaluate the safety and tolerability of AB-SA01, its proprietary investigational phage cocktail targeting Staphylococcus aureus (S. aureus) infections. […]
AmpliPhi Biosciences’ Bacteriophage Cocktail Shown to Prevent C. difficile Biofilm Formation and Reduce Colonization
/in Portfolio CompaniesMonday, September 12, 2016. Link here. NYSEMKT:APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, announced the publication of data from a preclinical study conducted by its collaborators at the University of Leicester demonstrating the therapeutic and prophylactic efficacy of AmpliPhi’s proprietary phage […]
Avita Medical’s Regenerative Skin Technology significantly reduces burn scars and healing time
/in Portfolio CompaniesNorthridge, CA, Perth, Australia and London, United Kingdom – 2 September 2016 Link here.
ADR – Thomas Lynch appointed as new Adherium chairman
/in Portfolio Companies1 September 2016: Link here. Adherium Limited (ASX:ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, today announced Mr Thomas Lynch as Adherium’s new Chairman, and Dr Doug Wilson as Adherium’s executive Medical Director. Mr Lynch’s appointment follows a global search for a high profile Director with broad […]
Rex Bionics – More Positive Data from RAPPER II
/in Portfolio Companies, Rex Bionics18 August 2016: Link here. Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is pleased to announce positive results from a second interim analysis of its RAPPER II clinical trial. RAPPER II is multi-centre, international trial to evaluate the feasibility and safety of the […]
Adherium and AstraZeneca Australia Commercial Pilot Program
/in Portfolio CompaniesMelbourne, Australia, 16th August 2016 Link here.
Rex Bionics – Confirmation of Strategic Investment by Maxhealth
/in Portfolio Companies, Rex Bionics05 August 2016: Rex Bionics plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is today pleased to announce that Maxhealth Medicine Co. Ltd has now deposited £1 million in escrow in relation to its subscription for 3,333,333 ordinary shares at 30p each. This £1 million will […]
Adherium Build Senior Leadership Team with New Chief Operating Officer and New Head of Corporate Development
/in Portfolio CompaniesMelbourne, Australia, 4 August 2016: Link here. Adherium has appointed its new Chief Operating Officer, Ross Bradding, and a new Head of Corporate Development, Julia Chambers.
AmpliPhi Biosciences Completes Enrollment of Its Investigational Phage Therapy Trial Targeting Staphylococcus aureus
/in Portfolio CompaniesWednesday, August 3, 2016 8:45 am EDT SAN DIEGO–(BUSINESS WIRE)–Link here. AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced it has completed enrollment of its Phase 1 clinical trial to evaluate the safety of AB-SA01, its proprietary phage cocktail targeting Staphylococcus aureus (S. […]